Meeting
2021 ASCO Annual Meeting
A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.
Authors
Vanessa Anne Eulo
Washington University in St. Louis, St. Louis, MO
Vanessa Anne Eulo , Breelyn A. Wilky , Jingqin Luo , Angela C. Hirbe , Mia C. Weiss , Peter John Oppelt , Sarah Abaricia , Jacqui Toeniskoetter , Tyler Ruff , Robert G Maki , Brian Andrew Van Tine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04551430
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS11583)
DOI
10.1200/JCO.2021.39.15_suppl.TPS11583
Abstract #
TPS11583
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu